ReviewJournal of clinical medicine2025
Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Sex-Specific Prevalence and Associated Factors of Dyslipidemia in Korean Adults: A Cross-Sectional Study.Health science reports · 2026Article
- Associations between prediabetes, type 2 diabetes and incident atrial fibrillation in patients with hypertension: Results from the Swedish Primary Care Cardiovascular Database.American journal of preventive cardiology · 2026Article
- Thrombaxane-B2 as a predictor marker of atrial fibrillation.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Conventional preoperative parameters associated with new-onset atrial fibrillation after TAVR: a comparative single-center study.Journal of cardiothoracic surgery · 2026Article
- Pharmacogenomics of Atherosclerotic Plaque: Pathophysiological Background and Therapeutic Perspectives.Current atherosclerosis reports · 2026Review
- Neuroimmune Regulation of Microvascular Inflammation: The Heart-Brain Axis, Mast Cells, and the Protective Role of Flavonoids-A Comprehensive Review.Biomedicines · 2026Review
- Lifestyle modification in atrial fibrillation: Mechanisms, phenotypes and ablation outcomes.Experimental physiology · 2026Review
- Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Systolic Versus Diastolic Echocardiographic Assessment of Epicardial Adipose Tissue for the Detection of Obstructive Coronary Artery Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- The Incremental Role of Stress Echocardiography in Valvular Heart Disease: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn's disease.Frontiers in immunology · 2026Review
- Association between remnant cholesterol inflammation Index and in-hospital New-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Pericardial Fat Radiomics to Predict Left Ventricular Involvement and Provide Incremental Prognostic Value in ARVC.Diagnostics (Basel, Switzerland) · 2025Article
- Protective Role of Lipid-Lowering Drugs in Breast Cancer: Effects on Cancer Incidence and Cardiotoxicity.Life (Basel, Switzerland) · 2025Review
- Atrial Septal Defect and Heart Rhythm Disorders: Physiopathological Linkage and Clinical Perspectives.Biomedicines · 2025Review
- Factor XI and Cancer: Physiopathological Linkage and Clinical Perspectives.Journal of clinical medicine · 2025Review
- Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications.Journal of clinical medicine · 2025Review
- Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.Biomedicines · 2025Review
- Cardiometabolic index as a predictor of major adverse cardiovascular events in atrial fibrillation: insights from a community-based cohort.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia is a metabolic disorder characterized by quantitative and/or qualitative abnormalities in serum lipid levels. Elevated serum cholesterol levels can modify the turnover and recruitment of ionic channels in myocytes and cellular homeostasis, including those of inflammatory cells. Experimental and clinical data indicate that inflammation is implicated in the pathophysiology of atrial remodeling, which is the substrate of atrial fibrillation (AF). Data about the association between increased lipid serum levels and AF are few and contrasting. Lipoprotein (a), adiposity, and inflammation seem to be the main drivers of AF; in contrast, low-density lipoproteins, high-density lipoproteins and triglycerides are not directly involved in AF onset. The present review aimed to describe the pathophysiological link between dyslipidemia and AF, the efficacy of lipid-lowering therapies in atherosclerotic cardiovascular disease (ASCVD) patients with and without AF, and the impact of lipid-lowering therapies on AF incidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.